A single Tearmaestro® liquid pulsation treatment significantly improves the primary outcome of patient-reported symptoms at 1 month, with concurrent benefits in tear film stability and meibomian gland function lasting up to 3 months. The treatment demonstrated a favorable safety profile, offering an efficient clinical option for MGD-related dry eye.
Yue et al. (Thu,) studied this question.